Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Febuxostat
Adenuric
Not routinely available
SMC (1153/16)
06/07/2016
Indication
For the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumour Lysis Syndrome (TLS).
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Formulation
120mg film-coated tablet
Comments
July 2016 - Not included on the LJF, because clinicians have not responded to an invitation to apply for formulary inclusion for this medicine.